{
  "id": "232606f882a163b6",
  "title": "Lilly Jaypirca ( pirtobrutinib ) met its primary endpoint in first - of - its - kind , head - to - head Phase 3 study versus Imbruvica ( ibrutinib ) \u2013 The Bubble",
  "description": "20251207T224500Z",
  "content": "",
  "source": "bubblear.com",
  "source_url": "https://bubblear.com/lillys-jaypirca-pirtobrutinib-met-its-primary-endpoint-in-first-of-its-kind-head-to-head-phase-3-study-versus-imbruvica-ibrutinib/26016/",
  "published_at": "20251207T224500Z",
  "fetched_at": "2025-12-08T00:22:54.837391+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Argentina",
  "raw_data": {
    "url": "https://bubblear.com/lillys-jaypirca-pirtobrutinib-met-its-primary-endpoint-in-first-of-its-kind-head-to-head-phase-3-study-versus-imbruvica-ibrutinib/26016/",
    "url_mobile": "",
    "title": "Lilly Jaypirca ( pirtobrutinib ) met its primary endpoint in first - of - its - kind , head - to - head Phase 3 study versus Imbruvica ( ibrutinib ) \u2013 The Bubble",
    "seendate": "20251207T224500Z",
    "socialimage": "",
    "domain": "bubblear.com",
    "language": "English",
    "sourcecountry": "Argentina"
  }
}